2-Ethyl-2,3-dihydrothiophene | 64655-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氢噻吩类
• 英文名称: 2-Ethyl-2,3-dihydrothiophene
• CAS: 64655-39-6
• 化学式: C₆H₁₀S
• 分子量: 114.21
• InChiKey: LOYLHCJBMKVWAV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS
  申请人：Venkataramani Chandrasekar

  公开号：US20100311794A1

  公开（公告）日：2010-12-09

  The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

  本发明提供了一种具有组蛋白去乙酰化酶（HDAC）抑制活性的一般式（I）化合物，包括该化合物的药物组合物，以及使用该化合物治疗疾病的方法。
• Inhibitors of VEGF receptor and HGF receptor signaling
  申请人：Saavedra Mario Oscar

  公开号：US20070004675A1

  公开（公告）日：2007-01-04

  The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions

  该发明涉及抑制VEGF受体信号和HGF受体信号。该发明提供了抑制VEGF受体信号和HGF受体信号的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病况的组合物和方法。
• [EN] FEM1B PROTEIN BINDING AGENTS AND USES THEREOF<br/>[FR] AGENTS SE LIANT À LA PROTÉINE FEM1B ET UTILISATIONS ASSOCIÉES
  申请人：UNIV CALIFORNIA

  公开号：WO2021183431A1

  公开（公告）日：2021-09-16

  Disclosed herein, inter alia, are compounds for binding FEMIB protein and uses thereof. In an aspect, provided herein is a pharmaceutical composition including a compound as described herein and a pharmaceutically acceptable excipient.

  本文披露了用于结合FEMIB蛋白的化合物及其用途。在一个方面，本文提供了一种包括本文描述的化合物和药用可接受的赋形剂的药物组合物。
• Inhibitors of protein tyrosine kinase activity
  申请人：Raeppel Stephane

  公开号：US20080004273A1

  公开（公告）日：2008-01-03

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  这项发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，该发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，导致受体信号传导的抑制，例如抑制VEGF受体信号传导和HGF受体信号传导。更具体地，该发明涉及用于抑制VEGF受体信号传导和HGF受体信号传导的化合物、组合物和方法。该发明还提供了用于治疗细胞增殖性疾病和病况的组合物和方法。
• ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS
  申请人：Graupe Michael

  公开号：US20100310500A1

  公开（公告）日：2010-12-09

  The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.

  本发明提供了一种具有组蛋白去乙酰化酶（HDAC）抑制活性的一般式（I）化合物，包括该化合物的药物组合物，以及使用该化合物治疗疾病的方法。